Skip to main content

Table 1 Patient and clinicopatholgic characteristics

From: Different protein expression associated with chemotherapy response in oropharyngeal cancer according to HPV status

Patient demographics Total n(%) HPV status, n(%) p16 status, n(%)
Positive Negative p Positive Negative p
Age (Y, median)     <0.001    <0.001
 ≥70Y 70 56 65 57 68
 Range 43-80 43-77 43-80 43-77 48-80
Gender     0.135    0.147
 Male 69 (93) 18 (86) 51 (96) 31 (89) 38 (97)
 Female 5 (7) 3 (14) 2 (4) 4 (11) 1 (3)
Alcohol     0.366    0.292
 Never/ social 56 (76) 17 (81) 39 (74) 28 (80) 28 (72)
 Heavy 18 (24) 4 (19) 14 (26) 7 (20) 11 (28)
Anatomic site     0.376    0.692
 Tonsil 47 (64) 15 (71) 32 (60) 24 (69) 23 (59)
 Soft palate 10 (13) 1 (5) 9 (17) 4 (11) 6 (15)
 Tongue base 17 (23) 5 (24) 12 (23) 7 (20) 10 (26)
Clinical stage     0.366    0.502
 III 18 (24) 4 (24) 14 (26) 9 (26) 9 (23)
 IV 56 (76) 56 (76) 39 (74) 26 (74) 30 (77)
T stage     0.181    0.062
 T1-2 45 (61) 15 (71) 30 (57) 25 (71) 20 (51)
 T3-4 29 (39) 6 (29) 23 (43) 10 (29) 19 (49)
N stage     0.305    0.601
 N0-1 19 (26) 4 (19) 15 (28) 9 (26) 10 (26)
 N2-3 55 (74) 17 (81) 38 (72) 26 (74) 29 (74)
Differentiation     0.346    0.099
 Well 23 (31) 4 (19) 19 (36) 14 (40) 10 (26)
 Moderate 19 (26) 6 (29) 13 (25) 6 (17) 17 (44)
 Poorly 8 (11) 4 (19) 4 (8) 10 (29) 9 (23)
 NA 24 (32) 7 (33) 17 (32) 5 (14) 3 (7)
PS     0.007    0.001
 0 42 (57) 17 (81) 25 (47) 27 (77) 15 (38)
 1 32 (43) 4 (19) 28 (53) 8 (23) 24 (62)
HPV        <0.001
 Positive 21 (28) 21 (100) 0 21 (60) 0
 Negative 53 (72) 0 53 (100) 14 (40) 39 (100)
p16     <0.001    
 Positive 35 (47) 21 (100) 0 35 (100) 0
 Negative 39 (53) 0 0 0 39 (100)  
Induction response     0.436    0.018
 CR 22 (30) 7 (33) 15 (28) 15 (43) 7 (18)
 Non-CR 52 (70) 14 (67) 38 (72) 20 (57) 32 (82)
RT dose (cGy)     0.429    0.470
 ≥6,500 43 (58) 6 (67) 37 (57) 21 (60) 22 (56)
 <6,500 31 (42) 3 (34) 28 (43) 14 (40) 17 (44)
RT type     0.070    0.289
 3D-RT 52 (80) 5 (56) 47 (84) 25 (76) 27 (84)
 IMRT 13 (20) 4 (44) 9 (16) 8 (24) 5 (16)
Treatment duration     0.501    0.092
 <4 months 29 (39) 3 (33) 26 (40) 17 (49) 12 (31)
 ≥4 months 45 (61) 6 (67) 39 (60) 18 (51) 27 (69)
  1. Abbreviation: CR, complete response.